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Abstract
Although significant progress has been made in the management of the hereditary
cancer  syndrome related  to  mutations  of  BRCA1,  two  fundamental  and  clinically
relevant questions regarding BRCA1-related cancer syndrome remain unresolved: (1)
What factors account for the tissue specificity of the BRCA1-related cancer risk? (2) How
does a mutation or loss of BRCA1 lead to the basal-like phenotype of breast cancer? This
review focuses  on recent  studies  in  BRCA1-related pathways  that  lead to  specific
characteristics of the hereditary cancer syndrome and discusses the current translational
evidence  for  exploiting  these  pathways  in  new  therapeutic  strategies.  Mounting
evidence suggests that estrogen signaling and metabolism, oxidative stress, specific
secondary mutations, and regulation of specific progenitor cells and transcriptional
programs are  critical  in  BRCA1-associated breast  cancer.  Strategies  geared toward
estrogen reduction may play a role in treatment and prevention. Therapies aimed at
mitigating oxidative stress  may be a strategy for  risk reduction,  while  cancer-cell-
specific sensitivity to oxidative stress may also be an opportunity for specific targeting.
BRCA1-related transcriptional regulation and signaling provide a number of therapeu-
tic targets, including the PI3-AKT and Notch pathways. Thus, significant opportunities
exist in translational and clinical research for developing the treatment strategies for the
management of BRCA1-related breast cancer.
Keywords: BRCA1, basal-like breast cancer, DNA repair, estrogen, reactive oxygen
species
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1. Introduction
In 1866, Pierre Paul Broca described the remarkable pedigree of his wife’s family in his treatise
Traité des Tumeurs: Of 19 women from five generations who lived to the age of 30 years, cancer
developed in 14 women, including nine cases of breast cancer [1]. The French physician and
surgeon observed: “This deadly predisposition, impossible to foretell, impossible to escape,
inaccessible to surgery, and until now even inaccessible to internal or medical treatment, is an
indication of a general state which precedes each local manifestation … in certain cases this
predisposition transmits itself by heredity through several generations” [1]. Progress was slow
for the next 100 years. Further identification of family pedigrees suggested the hereditary
passage of breast cancer, but this remained controversial [2]. With the second half of the
twentieth century came the recognition of a familial breast cancer syndrome that in some cases
could be associated with an autosomal dominant allele encoding a tumor suppressor gene [3].
In 1990, linkage analysis mapped the putative allele to chromosome 17q21, and the gene,
BRCA1, was finally cloned in 1994 [4, 5]. The identification of BRCA2 followed a similar
trajectory, with its localization to 13q12-13 in 1994 and cloning the following year [6, 7]. In
addition to BRCA1/2, a number of genes have been implicated in familial breast cancer with
varying degrees of conferred risk that are generally inversely related to population allele
frequency; BRCA1, for example, has rare mutations with high penetrance [8]. Since that time,
significant advances have been made in understanding the risks and mechanisms of BRCA1/2-
related carcinogenesis. For patients with BRCA1/2 mutations, estimates of lifetime cancer risk
widely vary due to different studies of cohorts and varying penetrance attributed to different
mutation-related phenotypes, family/genetic history, and environmental exposures. Cumula-
tive risk by 70 years of age for patients with germline BRCA1 mutations ranges between 46%
and 87% for breast cancer and between 27% and 63% for ovarian cancer, with the low-risk and
general population studies falling in the lower range of the estimate and high-risk families in
the upper range. For BRCA2 mutations, the risks are 31–56% and up to 11%, respectively [9].
Beyond female breast and ovarian cancer, BRCA1 mutations may also be associated with the
risk for melanoma, whereas BRCA2 is associated with male breast cancer, pancreatic cancer,
and prostate cancer [10].
A number of therapeutic strategies have been developed to manage hereditary breast cancer.
The National Comprehensive Cancer Network evidence-based guidelines provide an algo-
rithm for the management of hereditary breast cancer, including identification of high-risk
individuals and families, genetic testing, cancer screening, risk mitigation through prophy-
lactic salpingo-oophorectomy and possible mastectomy, locoregional and systemic treatment,
and ongoing surveillance [11]. Newer therapies and combination strategies are being designed
to target more specific features of the cancer genotype and phenotype. The use of PARP
inhibitors in the model of synthetic lethality to exploit deficiency in homologous repair in
BRCA1/2 deficient cells is one such example [12–15]. This targets one aspect of BRCA1/2
function, but the development of further strategies is desirable, especially as BRCA1-related
cancer and cancer risk have a more complicated etiology than defective homologous repair
alone. The BRCA1 cancer syndrome may be related to the myriad cellular processes in which
BRCA1 is involved, including recognition and repair of genomic damage, regulation of
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chromosome sorting and mitosis, control of cell-cycle checkpoints, protein ubiquitination, cell
signaling, and transcriptional regulation [16–20]. Further, abrogation of BRCA1 function can
be the result of a multitude of lesions and processes with variable penetrance and relative
hypomorphism, including mutations resulting in a premature stop codon with or without
mRNA transcription and expression of a truncated protein, mutations resulting in loss of the
function of particular functional domains, intronic mutations resulting in splice variants, large
rearrangements, variation in mRNA splicing, methylation and silencing of the gene, and
regulation by microRNA [21–23]. Although most BRCA1 mutant mRNAs have shortened half-
life, some BRCA1 mutant proteins are translated [24]. However, characterizing cellular
localization and function of these proteins is difficult. Staining for intracellular BRCA1 in
mutants is inconsistent, as patterns vary with different antibodies, fixation methods, and
methods of exposing epitopes, which may lead to a lack of correlation between BRCA1 staining
and qPCR levels [25, 26]. Despite nearly two decades of genetic testing, there remain a
significant number of variants of uncertain significance. Even when a mutation is established
as pathogenic, targeted therapies against DNA repair may not always be effective, as preclin-
ical data suggest in the case of at least one common pathogenic mutation, C61G [27].
Out of this complicated picture, two fundamental questions arise regarding specific charac-
teristics of the BRCA1-related cancer syndrome, both with the potential to guide cancer
prevention and therapy: (1) What accounts for the tissue specificity of the BRCA1-related
cancer risk? (2) How does mutation or loss of BRCA1 lead to the basal-like phenotype of breast
cancer, as opposed to the luminal phenotype of BRCA2 mutations? We searched PubMed for
English-language studies and reviews related to BRCA1 function, estrogen metabolism,
oxidative stress, basal-like breast cancer, and BRCA1-related therapy. Reference lists of selected
articles were searched to track the provenience of key ideas and findings.
2. BRCA1/2 and carcinogenesis
The best known and perhaps dominant roles for the BRCA proteins in tumor suppression lie
in the maintenance of chromosomal stability, a role played in nearly all tissues [28]. Both
BRCA1 and BRCA2 are essential for homologous repair, a high-fidelity repair mechanism for
double-stranded breaks and daughter strand gaps, lesions that can arise from DNA damage
and at stalled replication forks [29, 30]. Lack of BRCA proteins results in these lesions being
shunted into error-prone repair pathways resulting in chromosomal rearrangements and
deletions [30–32]. Both BRCA1/2 have additional roles in chromosomal stability: BRCA1
functions in the recognition of DNA damage and the recruitment and assembly of protein
complexes for repair of lesions, and BRCA2 stabilizes stalled replication forks to allow for
repair rather than degradation and prevents spontaneous hyperrecombination [28, 33, 34].
BRCA1 also heterodimerizes with BARD1 at the N-terminal ring domain, conferring E3
ubiquitin ligase activity and regulating mitotic spindle assembly; loss of this interaction also
results in loss of tumor suppressor activity [27, 35]. Dysregulation of the mitotic spindle
assembly as well as centrosome amplification, along with failure of the G2-M checkpoint, leads
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to defects in chromosome segregation, abnormal division, and aneuploidy [35, 36]. BRCA2
may also have a role in cell-cycle checkpoint control [37].
Maintenance of chromosomal stability alone cannot explain comprehensively the related
cancer syndrome beyond an increased risk of carcinogenesis. Other factors are needed to
account for the tissue tropism of BRCA1/2-related cancers as well as the particular phenotype
of BRCA1-related cancer: basal subtype cancer developing specifically in the epithelium of the
breast and papillary serous cancer developing most likely in the fimbria of the fallopian tube
—cancers that have similar mutational profiles and likely similar early driving events in
carcinogenesis [38]. Several explanations may account for the tissue specificity of the carcino-
genic potential. First, breast and fallopian tube cells are subject to a unique exposure resulting
in accumulating mutations and genomic damage, possibly related to the genotoxic effects of
estrogen metabolism and the generation of reactive oxygen species (ROS), or related to
abrogation of normal cell-cycle control in tissues periodically undergoing multiple cycles of
rapid proliferation. These tissues may provide an environment that is permissive for, or even
driving, cell survival and proliferation despite mounting genomic damage. Further, functions
of BRCA1 unrelated to genomic stability may contribute both to the tissue-specific risk as well
as the particular phenotype including transcription-related roles in the regulation of mammary
progenitor cells and moderation of the proliferative effects of estrogen signaling.
2.1. BRCA1 cancer tissue specificity: estrogen and oxidative stress
Maintenance of the genome alone cannot explain the tissue-specific nature of BRCA1-related
cancer risk. It is well documented that cumulative estradiol exposure is linked to lifetime risk
of the development of breast cancer [39]. Estrogen-linked carcinogenesis could be related to
the transcriptional program of estrogen signaling, which promotes cell proliferation, or to the
toxic side effects of estrogen metabolism. BRCA1 interacts with the classical estrogen signaling
pathway in combination with BARD1 by repressing ERα-related transcription through
ubiquitination, a function lost with deleterious mutations of the BRCA1 RING domain [40,
41]. However, estrogen signaling is not restricted to the nuclear receptors ERα and ERβ and
likely plays a role in estrogen receptor negative cancers. Recent studies have shown an
alternative mechanism of BRCA1 cell survival based on nonclassical binding of estrogen to
cytoplasmic and membrane-associated proteins with downstream effects preventing damage
from oxidative stress [42]. Gorrini et al. showed that both oxidative stress and estrogen induced
the expression of NRF2, a master regulator of antioxidant capacities, through the PI3K-AKT
pathway, and that NRF2 induced by estrogen was crucial for cell survival. They also showed
that apoptosis may be prevented in BRCA1 knockdown mammary epithelial cells with
exposure to estrogen [43, 44]. This is consistent with clinical observations that reduction in
estrogen load reduces risk of cancer in women carrying a BRCA mutation, even if BRCA1-
related cells are estrogen receptor negative [45].
BRCA1 mutants may be particularly sensitive to estrogen metabolites, and the early risk of
developing cancer reflects the rapid, uncorrected accumulation of genotoxic damage from
exposure to both estrogen metabolites and reactive oxygen species produced by oxidative
metabolism of estrogen through the catechol pathway, a topic reviewed by Yager and David-
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son [39]. Metabolism of estrogen by cytochrome P-450 enzymes, including some tissue-specific
enzymes, leads to the formation of estrogen-3,4-quinone, which can form stable DNA adducts
and depurinating DNA adducts resulting in mutagenesis. Reduction of oxidized estrogen
metabolites leads to reactive oxygen species, which may further damage DNA, proteins, and
lipids [39]. Recently, Santen et al. have shown in ER knockout mice the dose-dependent
accumulation of toxic estrogen metabolites and concordant rates of tumor formation along
with mitigation by estrogen reduction via oophorectomy or aromatase inhibitor treatment [46].
Further, Savage et al. showed that treatment with the estrogen metabolites, 2-hydroxyestradiol
and 4-hydroxyestradiol, resulted in double-strand breaks, produced primarily during S-phase,
and that BRCA1 deficiency, including both heterozygous and homozygous mutants, led to
increased double-strand breaks and loss of efficient repair [47]. Further, wild-type BRCA1
represses the expression of estrogen metabolizing genes, resulting in decreased damage to
DNA [47].
Reactive oxygen species (ROS) are produced during normal aerobic metabolism and multiple
other cellular processes. ROS and the redox state of a cell are also essential components in cell
signaling and homeostasis. Imbalance of pro- and antioxidant factors, whether from endoge-
nous sources or exogenous sources (e.g., UV radiation and tobacco), results in oxidative
damage to nucleic acids, amino acids, and fatty acids, and contributes to a number of disease
processes. Among the most common DNA lesions resulting from oxidative stress is 8-
oxoguanine, which results in a mutagenic template during DNA replication resulting in base
pair substitutions and stalling of RNA polymerase II at the site of the lesion with inhibition of
nucleotide excision repair [48, 49]. Bae et al. showed that BRCA1 has a role in the response to
oxidative stress by upregulating expression of antioxidant genes and enhancing the activity
of NRF2 [50]. Further, BRCA1 maintains balance of the cellular redox state, making cells more
resistant to exogenous oxidative stress. BRCA1 overexpression and deficiency result in
increased and decreased resistance to exogenous oxidative stress, respectively [50]. Besides
activating cellular defenses to oxidative stress, BRCA1/2 also mediate repair of DNA damage
resulting from oxidative stress. Le Page et al. showed that BRCA1- and BRCA2-deficient cells
are unable to repair 8-oxoG lesions and that reconstitution of wild-type BRCA proteins leads
to recovery of the transcription-coupled repair mechanism [49]. These studies suggest that
BRCA1 tumor suppression involves mitigating the damage of oxidative stress before it is
required to repair the resulting DNA lesions.
2.2. BRCA1 cancer phenotype: progenitor cells and transcriptional regulation
Tumors arising in the setting of a germline BRCA1 mutation share common features from the
level of genomic alterations, gene expression, histologic phenotype, clinical behavior and
prognosis, and response to therapy. Histologically, they are high grade with high mitotic index,
pushing tumor margins, central necrosis, and a lymphocytic infiltrate [51]. A subset of sporadic
tumors, often demonstrating a relative decrease in BRCA expression through mechanisms
other than germline loss, and arising in the same tissues as germline mutants, appears to share
this constellation of traits [52]. Turner et al. coined the term BRCAness to identify “the
phenotypes that some sporadic tumors share with familial-BRCA cancers” [52]. This is in
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contrast to BRCA2-related breast cancer, which has a significantly different gene expression
profile, and which is more typically lower grade, more differentiated, appearing later in life,
and of the luminal/ER-positive subtype [51, 53]. Interestingly, the relative risk profiles for
BRCA1 and BRCA2 mutations are also different, further suggesting different etiologic
mechanisms. Compared to the aged-matched general population, the relative risk for BRCA1
mutation carriers is greatest in the young population and approaches the population risk in
the later decades of life; the relative risk for BRCA2 remains constantly elevated over the
population risk throughout the patient’s lifetime [54].
BRCAness may be a feature related to the progenitor cell of origin from which these cancers
arise. Foulkes hypothesized that BRCA1 acting as a regulator of mammary stem cell function
may drive the phenotype of BRCA1-related cancers [55]. In this model, immortal mammary
stem cells absent a BRCA1 signal would maintain a relatively undifferentiated, proliferative
phenotype that would require very few additional genomic “hits” in order to become malig-
nant; genomic instability conferred by loss of BRCA1-mediated DNA repair functions would
account for the proclivity for malignant derangement and the early age of presentation. The
general model is appealing, although it appears more likely that BRCA1-associated cancer
arises from luminal epithelial progenitors, not mammary stem cells [56].
The mammary epithelium can be sorted into subgroups representing different stages of the
differentiation from multipotent mammary stem cell to mature luminal epithelium, which
requires BRCA1 for proper development [57]. Depletion of BRCA1 results in failure of
mammary cells to differentiate and form acini in culture, but increases cell proliferation [58].
Liu et al. showed that BRCA1 knockdown increases stem/progenitor cell population while
preventing mammosphere formation [59]. Furthermore, in human mammary tissue, BRCA1
heterozygotes showed lobules comprised of ALDH1 (stem cell marker) positive cells with
minimal ER expression and evidence of BRCA1 loss of heterozygosity. These lobules occurred
in normal tissue, showing that mammary progenitor cells can survive without BRCA1
expression and create atypical, nonmalignant lobules. This suggests that the tissue tropism of
BRCA1-related tumors is due to a permissive environment, possibly due to release of paracrine
factors from luminal epithelium, for the survival of BRCA1 negative cells [60].
Lim et al. [62] demonstrated that normal mammary cells sorted by basal and epithelial markers
showed varied potency and clonogenic activity in vivo corresponding to bipotent progenitor,
committed luminal progenitor, and mature luminal cells. These may represent the cells of
origin of the different subtypes of mammary epithelial tumors that can be segregated by gene
expression [53, 61]. Comparison of gene expression profiles between normal mammary
subpopulations of mammary stem cells, luminal progenitor cells, and mature luminal cells
showed significant associations with, respectively, claudin-low, basal, and luminal A and B
cancer cell populations [62]. Further analysis of these subtypes reveals few somatic mutations
common to all breast cancers, but within the well-defined subtypes, genetic and epigenetic
changes give rise to their common phenotypes [38]. These tumor subtypes can also be
segregated by clinical behavior, prognosis, and response to treatment [63].
Gene-expression profiles of BRCA1-associated tumors correlated most closely with luminal
progenitor cells and loss of BRCA1 in a mouse luminal breast cancer model leads to epithelial-
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mesenchymal transition (EMT), dedifferentiation, and basal tumor development [62, 64, 65].
BRCA1 transcriptionally regulates a number of genes associated with basal-like breast cancer,
including Notch ligands and receptors, with loss of BRCA1 associated with decreased luminal
differentiation and ER-α signaling and also with increased basal-like and proliferation markers
[66]. Increased Notch signaling due to BRCA1 loss may contribute to the basal-like phenotype
as well as suppression of apoptosis [67]. Wild-type BRCA1 represses expression of a number
of genes associated with basal-like and BRCA1-related cancers, including FOXC1, p-Cadherin,
and CK5 and 17 [68, 69]. The luminal progenitor, as the cell of origin for BRCA1-related cancer,
is consistent with an important role for ROS as mammary stem cells and multipotent progen-
itor cells have lower concentrations of ROS than more mature progenitor cells [70].
Around 80–90% of BRCA1 tumors are basal, as opposed to 10–15% of all tumors, although
may also sort with the claudin-low subtype [38, 71, 72]. Conversely, around 20% of basal tumors
show germline or somatic BRCA1/2 mutation [38]. BRCA1-related cancers exhibit common
mutational profiles. A total of 81–89% of BRCA1 tumors, both ER+ and ER−, have a loss of
heterozygosity of the wild-type allele, which is correlated with higher grade and increased
proliferation [73]. For cells lacking functional BRCA1, cell survival is generally dependent on
secondary mutations. BRCA1 tumors commonly show mutations of PTEN and TP53 allowing
cell proliferation to continue in spite of mounting genomic irregularities. These mutations
appear to follow a general evolutionary pattern preceding the loss of the WT BRCA allele [74].
This is significantly different than tumorigenesis in luminal cancers, with rare PTEN mutations
and late loss of TP53. Even without loss of wild-type allele, heterozygotes display altered gene
expression, including in genes related to cell differentiation and proliferation [75].
3. Developments in targeted therapy
Therapy for BRCA1/2 related tumors involves surgery, radiation, and systemic chemotherapy
and endocrine therapy. Specific treatment for cancer developing in the setting of BRCA1/2 has
targeted deficient DNA repair. Platinum-based chemotherapy creates intra- and interstrand
DNA crosslinks resulting in double-stranded breaks. In the absence of homologous repair, the
accumulation of genomic damage results in cell death. Pegylated liposomal doxorubicin has
also been shown to have a survival advantage [76].
PARP inhibitors have been used to exploit the DNA repair defect [13]. PARP-1 binds to DNA
strand breaks and signals DNA damage by hydrolyzing NAD+ to form poly(ADP-ribosyl) tails
on histones and itself, resulting in the recruitment of the protein machinery for repair [77].
PARP inhibitors include a nicotinamide moiety that competes with NAD+, inhibiting the
enzymatic function of PARP, and trapping the PARP enzyme at the site of DNA damage,
preventing repair [78]. Loss of PARP-mediated regulation and repair of single strand breaks
leads to stalled replication forks, and double strand breaks develop, which leads to cell death
in a process referred to as synthetic lethality. Loss of BRCA1 prevents homologous repair from
occurring; loss of PARP function results in loss of regulation of nonhomologous end joining,
which leads to error-prone repair, genomic instability, and cell death [79]. A number of clinical
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trials assessing the efficacy of PARP inhibitors in BRCA-mutated breast cancer are currently
underway, in metastatic disease as well as in the adjuvant and neoadjuvant setting (http://
www.cancer.gov/about-cancer/treatment/clinical-trials).
However, not all BRCA1-related tumors are sensitive to DNA damaging agents and PARP
inhibitors. BRCA1 deleterious mutations in the RING finger domain lose tumor suppressor
function related to loss of interaction with PALB but retain some homologous repair activity,
rendering them less responsive to PARP inhibitors and platinum chemotherapy [27]. There is
also evidence that BRCA1/2-associated tumors gain resistance to platinum and PARP inhibitor
therapy through mutations resulting in reversion to the wild-type sequence or other restora-
tion of the open reading frame [80]. Lord and Ashworth also review preclinical data suggesting
that loss of 53BP1 or the related RAP1-interacting factor 1 (RIF1), proteins involved in nonho-
mologous end joining, leads to reduced genomic damage from PARPi-induced nonhomolo-
gous end joining and at least partial restoration of homologous repair and survival for BRCA1-
deficient cells. However, clinical data supporting this mechanism are lacking [80].
Further specific treatment for BRCA1 cancer risk includes targeting estrogen production and
signaling and prophylactic surgery to eliminate or reduce the number of potential tumorigenic
cells. Bilateral salpingo-oophorectomy has been shown to significantly reduce the risk of breast
cancer incidence by about 50% and breast cancer mortality by 90% [45, 81]. The use of tamox-
ifen, independent of estrogen receptor status, reduced the risk of contralateral breast cancer
in BRCA1 mutation carriers with HR 0.38 (95% CI, 0.27–0.55) in a pooled prospective/retro-
spective cohort [82]. Specific therapy to prevent formation of ROS or toxic estrogen metabolites
without endocrine ablation or blockade present a possible target that would modify cancer
risk without the possible side effects and complications of surgery and iatrogenic menopause,
including loss of fertility. Alternatively, strategies that exploit increased oxidative stress in
tumor cells may provide strategy for targeted therapy. In normal cells, ROS are produced at
low concentrations and can be effectively neutralized by the antioxidant system of the cells. In
contrast, cancer cells produce elevated levels of ROS due to increased metabolic activity,
resulting in a state of chronic oxidative stress. As noted above, BRCA1-mutant cells have a
dysregulated response and increased sensitivity to oxidative stress as well as a decreased
ability to repair DNA lesions resulting from ROS. As such, induction of ROS-mediated damage
in cancer cells by proper pharmacological agents that either promote ROS generation beyond
the cellular antioxidative capacity or disable the cellular antioxidant system have been
considered as a “radical” therapeutic strategy to preferentially kill cancer cells [83]. Elesclomol,
a small molecule that increases ROS production in mitochondria and induces apoptosis, has
shown in vitro potential for treating breast cancer cells with defective DNA repair [84, 85].
The PI3K-AKT pathway is another target for therapy. PI3K is involved in both oxidative
stress and escape mechanisms of DNA repair from PARP inhibitors. Combination treatment
with PI3K and PARP inhibitors showed significant efficacy in inhibiting tumor cell growth
in vitro and reducing tumor volume in mouse models [86]. PI3-AKT also functions down-
stream of Notch, a critical cancer stem cell regulator associated with basal-like breast cancer,
in suppression of apoptosis [87, 88]. Although targeting the Notch pathway alone is not suf-
ficient to reduce proliferation or cause cell death, combination with inhibition of the EGFR
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pathway or AKT pathway results in enhanced cell death [88]. These results suggest that
combination therapies targeting signaling pathways implicated in basal-like breast cancer or
BRCA1-regulated cell function would provide new avenues for combating BRCA1-related
breast cancer.
4. Conclusion
A great volume of knowledge regarding the molecular functions of BRCA1 and BRCA2 has
developed in the last 20 years since the cloning of the genes. Despite some challenging issues
in understanding BRCA1-mutant breast cancer development, there is great potential for
advances in tying elucidated molecular pathways in cell and animal models to the clinical and
epidemiological presentation of BRCA1/2-related breast cancer ( Table 1). Such translational
advances may be exploited not only to advance the treatment of breast cancer but also to
diminish the risk described by Pierre Paul Broca—inaccessible to treat, impossible to escape—
so long ago.
Challenges in BRCA1-associated breast cancer Opportunities in BRCA1-associated breast cancer
1. Mechanisms for the tissue specificity of the
BRCA1-related cancer risk
2. Mechanisms for the unique BRCA1-related breast
cancer phenotype
3. Differential effects of BRCA1 mutations in different
mammary epithelial cell and breast cancer cell populations
4. Individualized breast cancer risk prediction for BRCA1
mutation carriers
1. Development of targeted therapy based on
hyperactive signaling pathways in BRCA1-associated
breast cancer
2. Improvement of synthetic lethal approaches in the
treatment of BRCA1-associated breast cancer
3. Prevention strategies based on BRCA1-associated
breast cancer biology
Table 1. Challenges and opportunities in BRCA1-related breast cancer research and treatment.
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